Shots:
- AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration
- The expanded collaboration will utilize AbCellera’s technology stack, which includes Trianni Mouse and OrthoMab protein engineering platform
- AbCellera will generate panels of Abs against up to 8 new targets across multiple indications, selected by Gilead
Click here to read full press release/ article | Ref: BusinessWire | Image: Business In Vancouver
The post Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications first appeared on PharmaShots.
